Tradestie Institutional Equity Comparison Engine
WST vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
WST Overall Edge
WST Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to West Pharmaceutical Services, Inc. (WST) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, WST trades at 40.2x Forward P/E with 22.9% operating margin (+8.7% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, WST sits in UNCLASSIFIED (13th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
WST
WST 40.2x vs LYRA N/M Fwd P/E
Growth & Margin Winner
WST
Op Margin 22.9% vs -25032.0% ยท YoY +8.7% vs -87.2%
Momentum & Technical Winner
WST
1Y +58.1% vs -94.3% ยท 52W Pos 88% vs 1%
Options & Structure Winner
WST
UNCLASSIFIED (13th %ile IV) vs UNCLASSIFIED (N/A IV)
WST
NYSE
West Pharmaceutical Services, Inc.
Surgical & Medical Instruments & Apparatus
$413.28
-1.08% 1D
Market Cap
$29.0B
1M Return
+7.65%
1Y Return
+58.13%
Forward P/E
40.2x
Unified AI Score
39.8 / 100
SELL
Tech 26.0
Fund 34.0
Flow 54.0
Mom 1.1
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
WST +58.13%
LYRA -94.34%
Spread: +79.09 pp (WST Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | WST Revenue | LYRA Revenue | WST Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $1.72B | N/A | 14.0% | N/A | WST |
| FY2019 | $1.84B | N/A | 16.1% | N/A | WST |
| FY2020 | $2.15B | N/A | 19.0% | N/A | WST |
| FY2021 | $2.83B | $0M | 26.6% | -15303.5% | WST |
| FY2022 | $2.89B | $0M | 25.4% | -4131.0% | WST |
| FY2023 | $2.95B | $0M | 22.9% | -4308.1% | WST |
| FY2024 | $2.89B | $0M | 19.7% | -6280.8% | WST |
| FY2025 | $3.07B | $0M | 19.0% | -7794.5% | WST |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | WST | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $29.0B | $2.3M | Larger Scale | WST |
| Trailing P/E Ratio Valuation | 46.7x | N/M | Lower Multiple | WST |
| Forward P/E Ratio Valuation | 40.2x | N/M | Lower Multiple | WST |
| Revenue Growth (YoY) Growth | +8.7% | -87.2% | Higher Growth | WST |
| Operating Margin (TTM) Profitability | 22.9% | -25032.0% | Higher Margin | WST |
| Net Profit Margin Profitability | 18.8% | 0.0% | Higher Margin | WST |
| Return on Equity (ROE) Capital Efficiency | 21.2% | -404.5% | Higher ROE | WST |
| 52-Week Range Position Momentum | 88% ($224โ$438) | 1% ($0โ$38) | Stronger Trend | WST |
| Beta / 30D Volatility Risk Regime | 0.46ฮฒ ยท 24% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | WST |
| Unified Institutional Score Composite Signal | 39.8 / 100 (SELL) | 52.2 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full WST vs LYRA Buy Guide
WST
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither WST nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.